Academic Journal
Oncolytic Virotherapy for Solid Tumors: Clinical Advances and Future Directions.
| Τίτλος: | Oncolytic Virotherapy for Solid Tumors: Clinical Advances and Future Directions. |
|---|---|
| Συγγραφείς: | Asawa P; Department of Medicine, Miller School of Medicine, Jackson Memorial Hospital, University of Miami, 1600 NW 10th Avenue, Miami, FL 33136, USA., Zheng X; Department of Medicine, Miller School of Medicine, Jackson Memorial Hospital, University of Miami, 1600 NW 10th Avenue, Miami, FL 33136, USA., Merchan JR; Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Avenue, Miami, FL 33136, USA. Electronic address: JMerchan2@med.miami.edu. |
| Πηγή: | Surgical oncology clinics of North America [Surg Oncol Clin N Am] 2026 Apr; Vol. 35 (2), pp. 385-398. Date of Electronic Publication: 2026 Jan 14. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Saunders Country of Publication: United States NLM ID: 9211789 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-5042 (Electronic) Linking ISSN: 10553207 NLM ISO Abbreviation: Surg Oncol Clin N Am Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Philadelphia : Saunders, c1992- |
| Ιατρικοί όροι (MeSH): | Oncolytic Virotherapy*/methods , Oncolytic Virotherapy*/trends , Neoplasms*/therapy , Neoplasms*/immunology , Oncolytic Viruses*/genetics, Humans ; Animals |
| Περίληψη: | Oncolytic viruses (OVs) are naturally occurring or genetically engineered viruses that selectively replicate in and destroy tumor cells while sparing normal tissues. This review provides an overview of the biological basis of OV therapy, including mechanisms of tumor oncolysis and immune modulation. We further discuss current clinical applications, emerging combination therapies, and the development of next-generation viral platforms. Finally, we examine the major barriers to OV clinical translation and outline emerging strategies to overcome them. The increasing momentum in oncolytic virotherapy, driven by advances in synthetic biology and immuno-oncology, underscores its potential to become a cornerstone of next-generation cancer treatments. (Copyright © 2025 Elsevier Inc. All rights reserved.) |
| Competing Interests: | Disclosure P. Asawa: The author declares no conflicts of interest related to the content of this article. X. Zheng: The author declares no conflicts of interest related to the content of this article. J.R. Merchan: Research support (institutional): Merck, United States, Exelixis, United States, Pfizer, United States, Arcus Biosciences, Kalivir Immunotherapeutic, Modex Therapeutics, Imugene, Tubulis, and Dynamicure Biotechnology. Advisory Board (Scientific): Merck. Royalties: Uptodate Inc. |
| Contributed Indexing: | Keywords: Immunotherapy; Oncolysis; Oncolytic virotherapy; Oncolytic virus |
| Entry Date(s): | Date Created: 20260328 Date Completed: 20260714 Latest Revision: 20260827 |
| Update Code: | 20260827 |
| DOI: | 10.1016/j.soc.2025.10.011 |
| PMID: | 41903995 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!